Product logins

Find logins to all Clarivate products below.


Psoriasis | Treatment Algorithms: Claims Data Analysis | Palmoplantar Pustular Psoriasis / Generalized Pustular Psoriasis | US | 2019

Pustular psoriasis is a rare subtype of psoriasis, typically seen as pustules that erupt generally across the body (generalized pustular psoriasis [GPP]) or are localized, typically on the hands and feet (palmoplantar pustular psoriasis [PPP]). Despite being more severe than general plaque psoriasis and potentially life-threatening, no drugs have been well studied for this psoriasis subtype and none are specifically indicated for PPP / GPP. Treatment typically includes topical corticosteroids, methotrexate, retinoids, and phototherapy. However, biologics, including TNF-alpha inhibitors and IL-17 inhibitors, and targeted orals used for plaque psoriasis are also increasingly being used to treat PPP / GPP.

QUESTIONS ANSWERED

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed PPP / GPP patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed PPP / GPP patients?
  • How have TNF-alpha inhibitors been integrated into the treatment algorithm, and what is their source of business?
  • What percentage of PPP / GPP patients receive drug therapy within one year of diagnosis, and how quickly do they receive it? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of PPP / GPP patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Related Market Assessment Reports

Report
Hyperkalemia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hyperkalemia (US)
Hyperkalemia is a potentially life-threatening condition characterized by a serum potassium concentration that exceeds 5.5 mEq/L. Despite various guidelines, a universally accepted consensus on the…
Report
Primary Biliary Cholangitis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Primary Biliary Cholangitis (US)
Primary biliary cholangitis (PBC) is a rare autoimmune liver disease characterized by inflammation and progressive damage to intrahepatic bile ducts, leading to bile buildup, followed by…
Report
Squamous Cell Carcinoma of the Head and Neck – Landscape & Forecast – Disease Landscape & Forecast (G7)
Squamous cell carcinoma of the head and neck (SCCHN) is the seventh most commonly diagnosed cancer. It encompasses a spectrum of heterogeneous tumors originating at multiple sites in the head and…
Report
Systemic Lupus Erythematosus – Current Treatment – Treatment Algorithms: Claims Data Analysis – Systemic Lupus Erythematosus (US)
Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organ systems. SLE symptoms range from general malaise to serious CNS and renal manifestations. Hydroxychloroquine…
Report
Chimeric Antigen Receptor (CAR) T-Cell Therapy – Access & Reimbursement – Access & Reimbursement – Chimeric Antigen Receptor (CAR) T-Cell Therapy (US)
Ever since Novartis’s Kymriah became the first chimeric antigen receptor (CAR) T-cell therapy approved by the FDA for a cancer indication (acute lymphoblastic leukemia) in 2017, this class of…